Trodelvy fails PhI­II lung can­cer study in blow to Gilead’s ADC ex­pan­sion plans

Gilead’s an­ti­body-drug con­ju­gate Trodelvy failed to sig­nif­i­cant­ly ex­tend sur­vival in a late-stage lung can­cer study, the phar­ma com­pa­ny said Mon­day morn­ing.

The Phase III EVOKE-01 study looked at Trodelvy in sec­ond-line metasta­t­ic non-small cell lung can­cer. It’s the first piv­otal read­out for the TROP2 an­ti­body-drug con­ju­gate in lung can­cer, a cat­e­go­ry that Gilead has eyed for Trodelvy. Gilead’s stock $GILD fell 10% in pre­mar­ket trad­ing Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER